Dr. Ferdinando E. Aspesi is Senior Partner at " Bridge Associates International -FEA" where he advises pharmaceutical companies’ management on quality strategy, organizational design as well as quality and compliance issues. He has been from 2014 to September 2016 Vice President, Senior Advisor to the Novartis Group Global Quality Head and has been until January 1, 2022 the Chairman of ASTM committee E-55 on Pharmaceutical and BioPharmaceutical manufacturing. In Novartis he was Global Quality Head Pharma Development covering GMP, GCP and Pharmacovigilance and Global Head Quality and Compliance OTC Division. Prior to his four years in Novartis, Dr. Aspesi was Global Head Quality and Compliance at Wyeth Pharmaceuticals and Global Head Quality and HSE for Aventis Pharmaceuticals. He has 44 years of experience in Drug Substance and Drug Product Quality Assurance, Quality Control, Research and Development, Drug Regulatory Affairs CMC and Analytical Development and Manufacturing. He has work experience in the United States, Germany, France, UK, Italy and South Africa. He holds a University Degree (Laurea) in Organic Chemistry from University of Milan (Italy).
In our industry, as in many others, the most important goal is developing and delivering a product that satisfies our customers. In our industry, the end customer is the patient.